Immunosuppressive Therapy in Heart Transplantation

View Sample PDF

Author(s): Yan Li (Cleveland Clinic, USA), April Yingfang Li (Northeast Ohio Medical University, USA), Ifeyinwa S. Nwankwo (Case Western Reserve University School of Medicine, USA), Zhi Huang (Cleveland Clinic, USA), Bin Zhang (Mayo Clinic, USA), Yun Lu (No. 1 Hospital of Lanzhou University, China)and Yali Yao (No. 1 Hospital of Lanzhou University, China)
Copyright: 2017
Pages: 20
Source title: Emerging Applications, Perspectives, and Discoveries in Cardiovascular Research
Source Author(s)/Editor(s): Ashim Malhotra (Pacific University, USA)and Shivani Soni (California State University, Fullerton, USA & Chapman University, USA & Alabama State University, USA)
DOI: 10.4018/978-1-5225-2092-4.ch012

Keywords: Cardiovascular Medicine / Medical Diagnosis and Practice / Medical Information Science Reference / Medicine & Healthcare

Purchase

View Immunosuppressive Therapy in Heart Transplantation on the publisher's website for pricing and purchasing information.

Abstract

Heart transplantation is a surgical procedure performed on patients with end-stage heart failure or other irreversible heart disease, Heart transplant prolongs the life of severe heart disease patients. Most of the receipts could survive more than 2-3 years, five-year survival rate could reach 70-80% with immunosuppressive therapy, rejection still an important problem after transplantation. Currently, traditional calcineurin inhibitors, antimetabolite agents, and steroids, wildly used after transplantation, the new generation of immunosuppressive medicines have been developed, and cell-based immunotherapy, as mesenchymal stem cell, myeloid-derived suppressor cells, dendritic cells, pluripotent cells and Treg cells are promising to be used in cellular immunotherapy in organ transplantation.

The IRMA Community

Research IRM

Immunosuppressive Therapy in Heart Transplantation

Purchase

Abstract

Related Content

IRMA Sponsors